Åslaug Helland
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NCT04300244) | Åslaug Helland | 2020-05-04 |
Track Åslaug Helland automatically
Every clearance here is in the API, with alerts when new ones post.